XXXX polymorphism influences the prognosis of @entity1204 @entity1 : a cohort study.

@entity72152 @entity1 @entity1204 @entity5 @entity406 @entity5456 @entity982
BACKGROUND: @entity5456 (formerly known as @entity5456 ) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between @entity72152 polymorphism of @entity5456 gene and decreased @entity1204 ( @entity1204 ) risk has been demonstrated. The aim of the current study was to test the hypothesis that @entity72152 polymorphism can influence the prognosis of @entity1204 @entity1 . METHODS: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on @entity406 -fixed and @entity982 -embedded @entity5 tissues. The influence of @entity1 ' genotype on overall survival and progression free survival were our main outcome measures. RESULTS: A total of 191 @entity1204 @entity1 were included in the final analysis. Overall survival differed significantly (P   =   0.003) among genotypes. At multivariate analysis, a significant (P   <   0.05) effect on overall survival was detected for FIGO stage, and @entity72152 polymorphism of @entity5456 gene. After grouping @entity1204 @entity1 according to adjuvant treatment, @entity72152 polymorphism resulted significantly (P   <   0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P   =   0.014) interaction between @entity72152 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P   =   0.090) towards significance was observed for @entity72152 polymorphism effect on progression free survival. CONCLUSIONS: @entity72152 polymorphism of @entity5456 gene influences independently the prognosis of @entity1204 @entity1 with a potential effect on @entity5 chemo-sensitivity.
